Newswise — HACKENSACK, NJ – Hackensack Meridian Hackensack University Medical Center’s Center for Memory Loss & Brain Health has started enrollment for a clinical trial for ATH-1017, an investigational medication for the treatment of mild to moderate Alzheimer’s disease as of August 3, 2021.
Ranked the #1hospital in New Jersey and the #7hospital in the New York metro area by U.S. News & World Report’s 2021-2022 “Best Hospitals” Honor Roll, Hackensack University Medical Center has New Jersey’s Best and only nationally-ranked Neurology & Neurosurgery programs and we are proud to contribute to the knowledge of the treatment of this disease by taking part in this groundbreaking clinical trial.
Alzheimer’s disease is a neurodegenerative condition that results in weakened brain connections and loss of brain cells. These problems cause dementia, which may include…
